MURRAY HILL, N.J., Dec 16, 2005 (BUSINESS WIRE) -- The Board of Directors of C. R. Bard, Inc. (NYSE-BCR) at
its December 14th meeting authorized the repurchase of up to $500
million of the company's common stock. This action replaces the
1,150,800 shares remaining under its most recent 5 million share
authorization, approved in December 2002. Share repurchases will be
made from time-to-time in the open market or through privately
C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management's current expectations, the accuracy of
which is necessarily subject to risks and uncertainties. These
statements are not historical in nature and use words such as
"anticipate", "estimate", "expect", "project", "intend", "forecast",
"plan", "believe", and other words of similar meaning in connection
with any discussion of future operating or financial performance. Many
factors may cause actual results to differ materially from anticipated
results including product developments, sales efforts, income tax
matters, the outcomes of contingencies such as legal proceedings, and
other economic, business, competitive and regulatory factors. The
company undertakes no obligation to update its forward-looking
statements. Please refer to our September 30, 2005 10-Q for more
detailed information about these and other factors that may cause
actual results to differ materially from those expressed or implied.
SOURCE: C. R. Bard, Inc.
C. R. Bard, Inc.
Eric J. Shick
Vice President, Investor Relations